PT3368658T - Expansão de células gama delta t residentes em tecidos não hematopoiéticos e utilizações destas células - Google Patents

Expansão de células gama delta t residentes em tecidos não hematopoiéticos e utilizações destas células

Info

Publication number
PT3368658T
PT3368658T PT167885391T PT16788539T PT3368658T PT 3368658 T PT3368658 T PT 3368658T PT 167885391 T PT167885391 T PT 167885391T PT 16788539 T PT16788539 T PT 16788539T PT 3368658 T PT3368658 T PT 3368658T
Authority
PT
Portugal
Prior art keywords
cells
expansion
gamma delta
hematopoietic tissues
resident
Prior art date
Application number
PT167885391T
Other languages
English (en)
Portuguese (pt)
Original Assignee
King S College London
The Francis Crick Institute Ltd
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1519198.4A external-priority patent/GB201519198D0/en
Priority claimed from GBGB1612731.8A external-priority patent/GB201612731D0/en
Application filed by King S College London, The Francis Crick Institute Ltd, Cancer Research Tech Ltd filed Critical King S College London
Publication of PT3368658T publication Critical patent/PT3368658T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
PT167885391T 2015-10-30 2016-10-31 Expansão de células gama delta t residentes em tecidos não hematopoiéticos e utilizações destas células PT3368658T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519198.4A GB201519198D0 (en) 2015-10-30 2015-10-30 Expansion of gamma delta t cells resident in non-haematopoietic tissue and uses of these cells
GBGB1612731.8A GB201612731D0 (en) 2016-07-22 2016-07-22 Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells

Publications (1)

Publication Number Publication Date
PT3368658T true PT3368658T (pt) 2022-08-17

Family

ID=57211532

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167885391T PT3368658T (pt) 2015-10-30 2016-10-31 Expansão de células gama delta t residentes em tecidos não hematopoiéticos e utilizações destas células

Country Status (16)

Country Link
US (2) US11618885B2 (enExample)
EP (2) EP3368658B1 (enExample)
JP (3) JP2018533373A (enExample)
KR (2) KR20250093576A (enExample)
CN (1) CN108473958A (enExample)
AU (2) AU2016344779B2 (enExample)
CA (1) CA3003077A1 (enExample)
DK (1) DK3368658T3 (enExample)
ES (1) ES2925261T3 (enExample)
IL (3) IL295838B2 (enExample)
MX (2) MX2018005207A (enExample)
MY (1) MY198084A (enExample)
PH (1) PH12018500926A1 (enExample)
PL (1) PL3368658T3 (enExample)
PT (1) PT3368658T (enExample)
WO (1) WO2017072367A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
EP3681996B1 (en) 2017-09-15 2024-08-07 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2020027193A1 (ja) * 2018-07-31 2020-02-06 国立大学法人三重大学 γδ型Ｔ細胞への遺伝子導入方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CN113423820A (zh) * 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
PH12021551475A1 (en) 2019-01-07 2022-05-02 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
CN112029719B (zh) * 2019-06-04 2024-05-03 北京医明佳和生物科技有限公司 纯化的双阴性t细胞及其制备和应用
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
CA3228168A1 (en) 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
WO2023053994A1 (ja) * 2021-09-29 2023-04-06 アイ ピース， インコーポレイテッド 幹細胞の製造方法
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
JPWO2023176896A1 (enExample) * 2022-03-18 2023-09-21
EP4504247A1 (en) 2022-04-04 2025-02-12 Gammadelta Therapeutics Ltd Novel gene armoring
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
CN121532496A (zh) 2023-07-20 2026-02-13 武田药品工业株式会社 用于制备γδT细胞的无网格方法
CN118165933B (zh) * 2024-05-14 2024-07-16 成都美杰赛尔生物科技有限公司 组合物、提高cd39-cd69-t细胞比例的方法
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
CN118853566B (zh) * 2024-09-26 2025-05-09 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤浸润淋巴细胞的培养方法及培养基

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421573T1 (de) 1998-11-04 2009-02-15 Therapure Biopharma Inc Verfahren zur herstellung von gamma delta t zellen
US20060246520A1 (en) * 2003-05-23 2006-11-02 Institut National De La Sante Et De La Recherche Medicale Gamma delta t cell-mediated therapy
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
PT2710123T (pt) * 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
CN104293734B (zh) * 2014-09-28 2018-01-09 上海云舜生物技术有限公司 一种人γδT细胞的制备方法
CN104711224A (zh) * 2015-01-09 2015-06-17 天津大学 一种提高人Vδ2T细胞扩增效率的体外培养方法及应用
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2016198906A1 (fr) * 2015-06-10 2016-12-15 Arcelormittal Acier a haute résistance et procédé de fabrication

Also Published As

Publication number Publication date
ES2925261T3 (es) 2022-10-14
US20180312808A1 (en) 2018-11-01
JP2018533373A (ja) 2018-11-15
PH12018500926A1 (en) 2018-11-05
IL295838A (en) 2022-10-01
US20230099491A1 (en) 2023-03-30
EP4148124A1 (en) 2023-03-15
MX2018005207A (es) 2018-09-19
AU2016344779A1 (en) 2018-06-14
HK1253954A1 (en) 2019-07-05
CN108473958A (zh) 2018-08-31
US11618885B2 (en) 2023-04-04
MX2022011003A (es) 2022-10-07
WO2017072367A1 (en) 2017-05-04
IL315329A (en) 2024-10-01
IL295838B2 (en) 2025-02-01
IL258985B2 (en) 2023-02-01
KR20180098235A (ko) 2018-09-03
RU2018119684A3 (enExample) 2020-03-17
KR102821381B1 (ko) 2025-06-13
JP2024069306A (ja) 2024-05-21
JP7451468B2 (ja) 2024-03-18
EP3368658B1 (en) 2022-07-06
KR20250093576A (ko) 2025-06-24
EP3368658A1 (en) 2018-09-05
PL3368658T3 (pl) 2022-11-28
CA3003077A1 (en) 2017-05-04
DK3368658T3 (da) 2022-08-01
AU2022283768A1 (en) 2023-02-02
MY198084A (en) 2023-07-31
RU2018119684A (ru) 2019-12-02
IL258985B (en) 2022-10-01
IL295838B1 (en) 2024-10-01
BR112018008293A2 (en) 2018-10-30
JP2022002517A (ja) 2022-01-11
AU2016344779B2 (en) 2023-01-05
IL258985A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
PT3368658T (pt) Expansão de células gama delta t residentes em tecidos não hematopoiéticos e utilizações destas células
IL255011A0 (en) Modified gamma delta cells and uses thereof
IL254734B1 (en) Modified t cells and methods of making and using the same
IL257105A (en) Modified cells and methods of therapy
SI3436048T1 (sl) Neoantigeni in načini uporabe
IL280863A (en) Autotaxin inhibitors and uses thereof
IL269334A (en) Improved t cell compositions and methods
EP2967683A4 (en) EXPANDABLE INTERMEDIATE IMPLANT AND METHOD OF USE
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
SI3258951T1 (sl) Anti-pvrig protitelesa in metode uporabe
IL240727B (en) Peptides and compositions for treatment of joint damage
IL249970B (en) Gamma delta t cells and uses thereof
IL265876A (en) Preparations that include 15-ohepa and methods of using them
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
EP3039131C0 (en) ENZYME COMPOSITION AND USES
IL245698B (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
SI3800177T1 (sl) Sestavki fenfluramina in njihovi načini priprave
BR112015023641A2 (pt) uso de micropartículas e células endotelial com descelularização de órgãos e tecidos
IL259761A (en) Imaging system unit cell and methods for dynamic range imaging
EP3359650A4 (en) ACTIVATION AND EXPANSION OF CELLS
CL2016000235A1 (es) Inhibidores de rorc2 y sus métodos de uso
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
IL259202A (en) Modified immune cells and uses thereof
DK2956471T3 (da) Il-1beta-hæmmersammensætning og anvendelse deraf